Loughborough University The Centre for Biological Engineering

Acquisition and Receipt of Biological Materials

Doc Ref: FS008.1

: HTA-PR-FORM/007

Version N°:

1.0

Issue Date:

ARF No: CBE/ARF/000 54

PART A: To be completed by the	Receiver (a separat	e form must be	completed for	each sample	type)		
A1. Details of Sample/Specimen	·						
Type/ID: (eg primary cell, cell line, tissu fluid, excreta, biological agent)	ne, body	HUVEC				☑Human □Animal	
Format / Quantity: (eg vials, slides, e	etc) 3 Vials	3 Vials					
Tissue site/Organ source:	Ubilical co	Ubilical cord				□N/A	
Batch N°:	C-12200	C-12200					
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)? If No, go to section A2.					☑Yes □No		
s the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?						☑Yes □No	
Is the material obtained for storage and use under a project specific NHS REC approval?						□Yes □No	
Is the material licensable under t	ırce below:				☑Yes □No		
☑HTA licensed organisation ☑0	Commercial Supplier	☑ Imported (fro	om outside Eng	gland, Wales o	or N.Ireland)		
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID	Lot N°: 446	l°: 446Z032, 449Z004, 449Z008			Jnique ID (Procuro): 0,S00214881,S002		
If Yes, provide Project Ref N°:	'Proof of c	'Proof of concept for separation of young from old (senescent) cells – impro					
If Yes, provide the name of the P	l: Alexandra	Alexandra Stolzing					
A2. Details of Receipt							
Date/Time of receipt	Date	29/06/21	29/06/21		12:30		
ID of Receiver	Name:	Katie Glenn	1	Dept:	CBE		
ID of Supplier/Provider	Name:	Promocell	- 1	Country:	Germany		
PART B: To be completed by the	Receiver						
B1. Inspection and Quarantine							
Has a biological risk assessment for the use of this material been approved?		☑Yes □No	Ref Number: CBE-199				
Physical integrity of the material(s) acceptable?		☑Yes □No	If No, describe action taken				
Quantity received correct?		☑Yes □No	If No, describe action taken				
Labelling correct and legible?		☑Yes □No	If No, describe action taken				
Is the relevant documentation	quality	or equivalent evidence of		☑Yes □No □N/A			
attached to this form?		Agreements to enable transfer of material eg MTA, SLA		□Yes □No ☑N/A			
If No, add reference or details to ensure traceability		retails/evidence/assurance of		☑Yes □No □N/A			

	Other (describe		□Yes □No ☑N/A	
Temporary storage - Quarantine location (as applicable)	Building/Room		CBE	
	Storage Unit ID	ID Bank 7		· , •
	Within storage	Within storage unit location ID Rack 5, Box B, Positions 6		5,7,8
	Date/Time of qu	uarantine		
Submitted by:	Signature:	Date: 29/06/21		
PART C: To be completed by	the departmental Q	uality Manager		建 种 医多种 第
C1. Quality Assurance Check	S			
Has the sample/specimen be	☑Yes □No □N/A			
Has the donor been screened	☑Yes □No □N/A			
Has the sample/specimen be	☑Yes ☐No ☐N/A			
Is there evidence that the supor other recognised certificat	☑Yes □No □N/A			
For HTA licensable material, i and use of the material unde	☑Yes □No □N/A			
Is there sufficient evidence to	□Yes □No ☑N/A			
C2. Approval for release from	n quarantine			
Can the material be released released for processing?	from quarantine and	transferred to des	signated storage area or	☑Yes □No
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Accept as is, but with extra controls		8 9
		Rework or repspecified require	process to meet the ements	
		☐Test to meet	specified requirements	
		☐Return to sup	pplier/provider	
		□Disposal		
		Building/Room		H25
If Yes, provide details of storage location (as applicable)		Storage Unit ID		
		Within storage (unit location ID	
		Database Refere	ènce	
		Date/Time of tra	ansfer	
Approved by:		Signature:	well	Date: 29/6/2/